<DOC>
	<DOC>NCT01793142</DOC>
	<brief_summary>This survey is conducted for preparing application material for re examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, and assessing the safety and efficacy profiles of VIVIANT in usual practice according to the Re-examination Regulation for New Drugs</brief_summary>
	<brief_title>Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice</brief_title>
	<detailed_description>continuous enrollment</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Postmenopausal osteoporosis and osteopenia patients Patients with active or past history of venous thromboembolic events including deep vein thrombosis, Patients with pulmonary embolism and retinal vein thrombosis</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>SERM</keyword>
</DOC>